Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance - PubMed (original) (raw)
. 2014 Nov;14(11):2467-77.
doi: 10.1111/ajt.12914. Epub 2014 Oct 13.
Affiliations
- PMID: 25311657
- PMCID: PMC4205183
- DOI: 10.1111/ajt.12914
Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance
D Hongo et al. Am J Transplant. 2014 Nov.
Abstract
The goal of the study was to elucidate the cellular and molecular mechanisms by which a clinically applicable immune tolerance regimen of combined bone marrow and heart transplants in mice results in mixed chimerism and graft acceptance. The conditioning regimen of lymphoid irradiation and anti-T cell antibodies changed the balance of cells in the lymphoid tissues to create a tolerogenic microenvironment favoring the increase of natural killer T (NKT) cells, CD4+ CD25+ regulatory T cells and Gr-1+ CD11b+ myeloid-derived suppressor cells (MDSCs), over conventional T cells (Tcons). The depletion of MDSCs abrogated chimerism and tolerance, and add back of these purified cells was restorative. The conditioning regimen activated the MDSCs as judged by the increased expression of arginase-1, IL-4Rα and programmed death ligand 1, and the activated cells gained the capacity to suppress the proliferation of Tcons to alloantigens in the mixed leukocyte reaction. MDSC activation was dependent on the presence of host invariant NKT cells. The conditioning regimen polarized the host invariant NKT cells toward IL-4 secretion, and MDSC activation was dependent on IL-4. In conclusion, there was a requirement for MDSCs for chimerism and tolerance, and their suppressive function was dependent on their interactions with NKT cells and IL-4.
Keywords: Basic (laboratory) research/science; bone marrow/hematopoietic stem cell transplantation; immunosuppression/immune modulation; immunosuppressive regimens; induction; macrophage/monocyte biology: activation; tolerance: chimerism; tolerance: mechanisms.
© Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.
Conflict of interest statement
Disclosure
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.
Figures
Figure 1. An imbalance favoring NKT cells, Tregs and MDSCs over Tcon cells and upregulation of negative costimulatory receptors creates a tolerogenic microenvironment after TLI/ATS conditioning
(A) Experimental scheme: BALB/c hosts were given donor C57BL/6 neonatal heart transplants (HTX) on day 0, and ATS was injected i.p. on days 0, 2, 6, 8, and 10. Hosts were conditioned over 14 days with 10 doses of 240cGy each. Some hosts were depleted of CD11b+Gr-1+ cells (MDSCs) with a single dose of anti- Gr-1 mAb (280 μg i.p. on day13). On day 15, 50 × 106 C57BL/6 donor bone marrow cells were injected intravenously (BMT), and chimerism and heart graft survival were monitored thereafter. (B) Representative FACS patterns of showing changes in the phenotypes of CD4+ and CD8+ T cell subsets, CD4+CD25+Tregs, CD4+CD1dtetramer+NKT cells, and Gr-1+CD11b+ MDSCs in the spleen of untreated normal wild type mice, hosts conditioned with TLI and ATS without transplantation or with combined bone marrow and heart allografts (TX, SPLEEN) on day 5 after the completion of TLI. Boxes show percentages of each cell type. Arrows shows gating of cells from a box. (C) Mean (± SEM) percentages of CD11b+Gr-1+ cells, TCR αβ +, CD4+CD1dtetramer+NKT, and CD4+CD25+ cells in the spleen of untreated (UNT) controls, of TLI and ATS conditioned BALB/c (TLI/ATS), and of TLI and ATS conditioned and transplanted (TX) hosts (day 5 after injection of donor bone marrow cells) (Upper panels and lower panels respectively) (UNT, N= 8; TX, N= 10; TLI/ATS, N= 8).
Figure 2. Depletion of MDSCs abrogates tolerance to combined bone marrow and heart transplants
(A) Representative spleen FACS patterns of Gr-1 versus CD11b and F4/80 staining are shown in untreated wild type mice, transplanted wild type hosts without anti- Gr-1 mAb treatment (WT TX), and transplanted wild type hosts with anti- Gr-1 mAb treatment. Patterns are also shown for peripheral blood mononuclear cells (PBMCs). Two days prior to end of TLI conditioning (day 13), BALB/c hosts were given a single injection of anti- Gr-1 mAb antibody (280 μg/ml/mouse) intraperitoneally, and spleen cells were obtained for analysis 24 hours after the injection. (B) Heart allograft survival in untreated (Non depl, WT TX, N= 10), or treated with anti- Gr-1 mAb (day 13) (Anti- Gr-1 depl + No add back, N= 8) or treated with anti- Gr-1 mAb and given an add back of sorted (1 × 106) MDSCs (CD11b+Gr-1+) cells (Depl+MDSCs add back, N= 8) from TLI/ATS conditioned wild type mice at the time of donor bone marrow infusion. (C) Shows the mean percentage of donor type cells (H-2Kb+) among peripheral blood mononuclear cells (PBMC) at day 28 after injection of donor bone marrow cells in non depleted, anti- Gr-1 depleted alone, or anti- Gr-1 depleted hosts given an add back of sorted (1 × 106) MDSCs cells. Data are from 3 independent experiments. * p< 0.05, ** p< 0.01, *** p< 0.001
Figure 3. NKT cells regulate Ly6G expression on MDSCs after transplantation
(A) Representative FACs staining of Ly6G versus Ly6C among CD11b+Gr-1+ cell subsets (Gr-1 hi vs Gr-1lo) in the spleen of untreated hosts (UNT WT, N= 12), or in wild type (WT TX, N= 10) or CD1d−/− hosts (CD1d−/− TX, N= 12) after conditioning and transplant. Four subgroups of Gr-1hi or Gr-1lo CD11b+ cells were enclosed in boxes labeled 1, 2, 3, and 4 with percentages shown; Ly6GhiLy6Chi (1), Ly6GhiLy6Clo (2), Ly6GloLy6Clo (3), and Ly6GloLy6Chi (4). (B) Bar graphs showing mean (± SEM) percentages of Ly6G+ Ly6C+ cell subgroups in boxes 1–4 among Gr-1hi cells. (C) Bar graphs show among Gr-1lo cells.
Figure 4. Upregulation of PDL1, Arginase-1, and IL-4Rα on MDSCs after transplantation is dependent on NKT cells
(A–C) Representative histogram plots showing the expression of PDL1, arg-1 (arginase-1), and IL-4Rα (interleukin- 4 receptor alpha) on gated CD11b+Gr-1+ cells from untreated wild type mice (UNT WT, N= 8), or transplanted wild type mice (WT TX, N= 10), or transplanted CD1d−/− mice (CD1d−/− TX, N= 12) 12 days after bone marrow infusion. (D –F) Bar graphs showing means (± SEM) of mean fluorescence intensity (MFI) measurements of PDL-1, arg-1, and IL-4Rα on CD11b+Gr-1+ cells in spleen.
Figure 5. The increase in MDSCs after transplantation is transient
(A–B) The mean (± SEM) percentages of CD11b+Gr-1hi and CD11b+Gr-1lo in the spleen (A) and among PBMCs (B) of TLI/ATS conditioned and transplanted wild type hosts at different time points (CD11b+Gr-1hi, N= 15; CD11b+Gr-1lo, N= 15). Data represents 5 independent experiments.
Figure 6. MDSC suppression of alloreactivity in vitro is dependent on NKT cells and IL-4
(A) Representative FACS patterns showing the CD11b+Gr-1+ enrichment and sorting for assay of in vitro suppression in the mixed leukocyte reactions (MLR). (B) Representative CFSE histogram plots showing CD4+ and CD8+ T cell proliferation in the presence or absence of sorted BALB/c MDSCs (2 × 105) from untreated wild type mice, N= 8 (WT T/A), TLI and ATS conditioned wild type mice N=8 (UNT WT), or TLI and ATS conditioned CD1d−/− mice, N= 10 (CD1d−/− T/A), or TLI and ATS conditioned Jα18−/− mice, N= 8 (Jα18−/− T/A), or TLI and ATS conditioned IL-4−/− mice, N= 5 (IL-4−/− T/A) or TLI and ATS conditioned IL-4−/− mice given an intravenous injection of 0.5 × 106 wild type NKT cells on day 15 after completion of TLI, N= 5 (IL-4−/− T/A + NKT) in day 5 cultures. There were 2×105 C57BL/6 responders (R) cells and 4×105 BALB/c stimulator (S) cells in MLR cultures. The percentages of dull CFSE cells are shown. (C) Mean (± SEM) percentages of CFSE+ dull cells among gated CD4+ and CD8+ T cells after in vitro culture.
Comment in
- Innate immune cell collaborations instigate transplant tolerance.
Ochando JC, Turnquist HR. Ochando JC, et al. Am J Transplant. 2014 Nov;14(11):2441-3. doi: 10.1111/ajt.12912. Epub 2014 Oct 13. Am J Transplant. 2014. PMID: 25311574 No abstract available.
Similar articles
- Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants.
Hongo D, Tang X, Dutt S, Nador RG, Strober S. Hongo D, et al. Blood. 2012 Feb 9;119(6):1581-9. doi: 10.1182/blood-2011-08-371948. Epub 2011 Dec 15. Blood. 2012. PMID: 22174155 Free PMC article. - Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation.
van der Merwe M, Abdelsamed HA, Seth A, Ong T, Vogel P, Pillai AB. van der Merwe M, et al. J Immunol. 2013 Dec 1;191(11):5764-76. doi: 10.4049/jimmunol.1302191. Epub 2013 Nov 4. J Immunol. 2013. PMID: 24190658 Free PMC article. - Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion.
Higuchi M, Zeng D, Shizuru J, Gworek J, Dejbakhsh-Jones S, Taniguchi M, Strober S. Higuchi M, et al. J Immunol. 2002 Nov 15;169(10):5564-70. doi: 10.4049/jimmunol.169.10.5564. J Immunol. 2002. PMID: 12421933 - Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients.
Jensen KP, Hongo DA, Ji X, Zheng P, Pawar R, Wu TH, Busque S, Scandling JD, Shizuru JA, Lowsky R, Shori A, Dutt S, Waters J, Saraswathula A, Baker J, Tamaresis JS, Lavori P, Negrin R, Maecker H, Engleman EG, Meyer E, Strober S. Jensen KP, et al. Blood Adv. 2021 Sep 14;5(17):3290-3302. doi: 10.1182/bloodadvances.2020003669. Blood Adv. 2021. PMID: 34432869 Free PMC article. - Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
Bruno A, Mortara L, Baci D, Noonan DM, Albini A. Bruno A, et al. Front Immunol. 2019 Apr 18;10:771. doi: 10.3389/fimmu.2019.00771. eCollection 2019. Front Immunol. 2019. PMID: 31057536 Free PMC article. Review.
Cited by
- Targeting Macrophages in Organ Transplantation: A Step Toward Personalized Medicine.
Owen MC, Kopecky BJ. Owen MC, et al. Transplantation. 2024 Oct 1;108(10):2045-2056. doi: 10.1097/TP.0000000000004978. Epub 2024 Mar 12. Transplantation. 2024. PMID: 38467591 Review. - Antitumor immunostimulatory activity of the traditional Chinese medicine polysaccharide on hepatocellular carcinoma.
Liu Y, Wu J, Hao H. Liu Y, et al. Front Immunol. 2024 Feb 22;15:1369110. doi: 10.3389/fimmu.2024.1369110. eCollection 2024. Front Immunol. 2024. PMID: 38455058 Free PMC article. Review. - Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients.
Rotolo A, Whelan EC, Atherton MJ, Kulikovskaya I, Jarocha D, Fraietta JA, Kim MM, Diffenderfer ES, Cengel KA, Piviani M, Radaelli E, Duran-Struuck R, Mason NJ. Rotolo A, et al. Cell Rep Med. 2023 Oct 17;4(10):101241. doi: 10.1016/j.xcrm.2023.101241. Cell Rep Med. 2023. PMID: 37852175 Free PMC article. - Helical TomoTherapy Total Lymphoid Irradiation and Hematopoietic Cell Transplantation for Kidney Transplant Tolerance in Rhesus Macaques.
Kaufman DB, Forrest LJ, Fechner J, Post J, Coonen J, Haynes LD, Haynes WJ, Christensen N, Zhong W, Little CJ, D'Alessandro A, Fernandez L, Brunner K, Jensen K, Burlingham WJ, Hematti P, Strober S. Kaufman DB, et al. Transpl Int. 2023 Jun 22;36:11279. doi: 10.3389/ti.2023.11279. eCollection 2023. Transpl Int. 2023. PMID: 37426429 Free PMC article. - Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies.
Bhardwaj V, Ansell SM. Bhardwaj V, et al. Front Cell Dev Biol. 2023 Apr 5;11:1129343. doi: 10.3389/fcell.2023.1129343. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37091970 Free PMC article. Review.
References
- Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358(4):362–368. - PubMed
Publication types
MeSH terms
Grants and funding
- P01HL-075462/HL/NHLBI NIH HHS/United States
- P01 HL075462/HL/NHLBI NIH HHS/United States
- P01-CA-4960523/CA/NCI NIH HHS/United States
- R01 AI037683/AI/NIAID NIH HHS/United States
- P01 CA049605/CA/NCI NIH HHS/United States
- R01-AI-037683/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials